Nuwellis Inc vs Vanguard High Dividend Yield ETF — how do they compare? Nuwellis Inc trades at $1.49 (market cap $522.76K), while Vanguard High Dividend Yield ETF trades at $166.57. The key difference: Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | VYM | |
|---|---|---|
Market Cap | $522.76K | — |
Sector | Technology | — |
52-Week High | $220.50 | $166.14 |
52-Week Low | $1.42 | $136.63 |
Enterprise Value | -$1.29M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
VYM trades at $165.63, up 0.52% today, near its 52-week high with strong bullish momentum from moving averages. The ETF's technicals show overbought RSI signals but positive ADX trends, while recent news highlights its role in retirement income strategies. A dividend of $0.98 is scheduled for June 2026, reinforcing its income focus amid institutional adjustments.
Outlook remains positive for income-seeking investors due to VYM's dividend reliability and sector diversification, though overbought conditions and underperformance versus the S&P 500 pose risks. Key opportunities include sustainable yield; risks involve market volatility and interest rate sensitivity.
Trailing returns across standard periods
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →